Drug Trial Radar · NCT00520806
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
Last checked: Nov 20, 2026Latest source record: Oct 30, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,161
Actual
Start
Oct 2007
Primary completion
Sep 2012
Study completion Sep 2012
Sponsor
- Lead sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companiesIndustry
- Sponsor type
- Industry
- First posted
- Aug 27, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure
Conditions
- Heart Failure, Congestive
Interventions
RelaxinDrug
Intravenous infusion for 48 h at 30 ug/kg/day
PlaceboDrug
Intravenous infusion for 48 h
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relief of dyspnea in acute heart failureTime frame: Up to day 5
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Northwestern University
Chicago, Illinois
Wayne State University/Detroit Receiving Hospital
Detroit, Michigan
Heart Institute
Safed, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.